Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of fexofenadine, a second-generation antihistamine, and fluticasone propionate, a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. This combination is used primarily for the treatment of allergic rhinitis. Fexofenadine works by antagonizing histamine H1 receptors to reduce symptoms such as sneezing, runny nose, and itchy eyes, while fluticasone propionate provides anti-inflammatory effects. The combination is effective because fexofenadine starts working within 2 hours, while fluticasone propionate can take up to 2 weeks to reach full effectiveness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fexofenadine + fluticasone propionate.